Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial (Q68019501)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1505913%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

title

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1505913%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

1 reference

placebo-controlled trial

1 reference

inferred from title

sclerosing cholangitis

1 reference

primary sclerosing cholangitis

inferred from title

1 reference

U. Beuers

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1505913

3 October 2022

U. Spengler

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1505913

3 October 2022

W. Kruis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1505913

3 October 2022

U. Aydemir

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1505913

3 October 2022

B. Wiebecke

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1505913

3 October 2022

W. Heldwein

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1505913

3 October 2022

M. Weinzierl

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1505913

3 October 2022

G. R. Pape

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1505913

3 October 2022

T. Sauerbruch

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1505913

3 October 2022

G. Paumgartner

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1505913

3 October 2022

language of work or name

English

0 references

publication date

1 September 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1505913%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1505913%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1505913%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1505913%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

page(s)

707-714

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1505913%20AND%20SRC:MED&resulttype=core&format=json

Medical approaches to primary sclerosing cholangitis

20 September 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

The 30-minute aminopyrine breath test: optimization of sampling times after intravenous administration of 14C-aminopyrine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Differential expression of MHC class II subregion products on bile duct epithelial cells and hepatocytes in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Ursodeoxycholic acid for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Primary sclerosing cholangitis: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Natural history and prognostic variables in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

The effects of intraduodenal bile acid administration on biliary secretion of ionized calcium and carbonate in man

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Tauroursodeoxycholic acid inhibits the cytosolic Ca++ increase in human neutrophils stimulated by formyl-methionyl-leucyl-phenylalanine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Increased expression of major histocompatibility antigens in the liver as a result of cholestasis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Expression of androgen receptor mRNA in human hepatocellular carcinomas and hepatoma cell lines

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Role of MHC gene products in immune regulation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160315

7 January 2021

Identifiers

DOI

10.1002/HEP.1840160315

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1505913%20AND%20SRC:MED&resulttype=core&format=json

20 September 2019

1 reference